[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypotension-and-shock\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypotension-and-shock":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,85,118],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100617708","phase-4-dopamine-vs-norepinephrine-for-hypotension-in-neonates-with-pulmonary-hypertension-done-100617708",false,"NCT07322133","Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE)","Dopamine vs. Norepinephrine in Term and Late Preterm Neonates With Hypoxemic Respiratory Failure and Systemic Hypotension Due to Pulmonary Hypertension: A Pilot Trial","DONE","Inclusion Criteria:\n\n1. Postmenstrual age \\> 34 6\u002F7 weeks and Postnatal age ≤ 28 days\n2. On respiratory support (Invasive mechanical ventilation, NIPPV, CPAP, HFNC ≥ 2 LPM) and FiO2 ≥ 0.3\n3. Echocardiographic evidence of pulmonary hypertension\n4. Mean arterial pressure below the threshold for gestational age despite a 10-20 mL\u002Fkg fluid bolus\n\nPermissible Comorbidities: CDH, trisomy 21, HIE on hypothermia, PDA, PFO\u002FASD, VSD \\\u003C 2 mm\n\nExclusion Criteria:\n\n1. Gestational age \\\u003C 32 weeks\n2. Severe hypoxic respiratory failure (OI \\> 35 or SpO2 \\\u003C 75% on 100% FiO2 for \\> 60 minutes)\n3. Lethal anomalies (e.g., trisomy 13 or 18)\n4. Complex congenital heart disease beyond specified criteria","ALL","28 Days",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This pilot randomized clinical trial compares dopamine and norepinephrine as first-line vasoactive therapies in term and late preterm neonates with pulmonary hypertension associated with hypoxemic respiratory failure and systemic hypotension. Systemic hypotension is a common and clinically significant complication of persistent pulmonary hypertension of the newborn (PPHN) and frequently requires vasopressor support to maintain adequate systemic perfusion. Dopamine is commonly used in this setting; however, prior animal experimental and clinical data suggest it may increase pulmonary vascular resistance, potentially worsening right ventricular afterload and hypoxemia. Norepinephrine may preferentially increase systemic vascular resistance with less effect on the pulmonary circulation. This study evaluates short-term hemodynamic and oxygenation responses following initiation of dopamine or norepinephrine.",[27,28,29],"Hypotension and Shock","Pulmonary Hypertension of the Newborn (PPHN)","Hypoxemic Respiratory Failure",[31,32,33],"Pulmonary Hypertension","Systemic Hypotension","Vasopressor","RECRUITING","2026-02-05",{"date":37,"type":38},"2026-02-10","ACTUAL",{"date":40,"type":21},"2026-06-01",{"date":42,"type":21},"2028-01-31",{"name":44,"class":45},"University of California, Davis","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":69,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100510835","phase-3-early-initiated-vasopressor-therapy-in-the-emergency-department-100510835","NCT05931601","Early Initiated Vasopressor Therapy in the Emergency Department","Early Initiated Vasopressor Therapy vs. Standard Care of Primarily Fluid Therapy in Hypotensive Patients in the Emergency Department - A Pragmatic, Multi-center, Superiority, Randomized Controlled Trial","VASOSHOCK","Inclusion Criteria:\n\n* At least 18 years of age\n* Signs or suspicion of hypotension or shock (of any type such as septic, vasodilatory or hypovolemic not included in the exclusion criteria) defined as:\n\n  1. SBP \\\u003C 100mmHg or MAP \\\u003C 65 mmHg combined with lactate \\> 2.0 mmol\u002FL,\n  2. Physician defined blood pressure for the individual patient combined with a lactate \\> 2.0 mmol\u002FL\n  3. Either SBP \\\u003C 100mmHg or MAP \\\u003C 65mmHg with obvious signs of shock with any lactate level evaluated by either two non-specialist physicians (e.g. registrar medical doctors) or a specialist physician.\n* Received at least 500ml of intravenous fluid before study inclusion (Including prehospital administration) within the first 4 hours of ED arrival.\n* Clinical Frailty Score (CFS) of ≤4. If CFS is ≥5 and the treating physician find the patient suitable for ICU admittance, the participant can be enrolled, if the on-call ICU doctor would accept the patient for ICU admittance. If the treating physician is unsure of ICU eligibility, regardless of CFS score, the patient should be consulted with the ICU consultant before study inclusion.\n\nExclusion Criteria:\n\n* Cardiogenic, anaphylactic, haemorrhagic, or neurogenic shock suspected by the treating physician.\n* Fertile women (\\\u003C60 years of age) with positive urine human gonadotropin (hCG) or plasma-hCG or women breastfeeding.\n* Patient deemed terminally ill or with a severe co-morbid status resulting in non-eligibility for ICU admittance decided by either the treating physician or ICU consultant.\n* Known allergy to noradrenaline.","18 Years",{"count":57,"type":21},320,[59],"PHASE3","The goal of this pragmatic, multi-center, superiority, randomized clinical trial is to compare early treatment with peripheral (through a vein) infused noradrenaline (a natural hormone that increases blood pressure) with fluid only therapy in patients with hypotensive and shock in the Danish and Swedish Emergency Departments (ED).\n\nThe main questions it aims to answer are:\n\nIf early initiated noradrenaline in non-bleeding hypotensive patients presenting in the ED can\n\n* Improve time to shock control.\n* Reduce the need for ICU admittance.\n* Decrease mortality.\n\nParticipants will be included by the clinical staff and treated urgently with either noradrenaline or usual treatment during their Emergency Department stay.\n\nAfter completion of the treatment in the Emergency Department, patient data will be extracted from the bed-side measurements, electronic health records and national registers.\n\nPatients will be contacted by the research staff 1 year after study inclusion to answer brief questions about their daily physical function and ability to care for themselves.\n\nResearchers will compare with patients receiving fluid therapy only, as this is the usual standard of care in Danish and Swedish Emergency Departments.",[62,63,64,27,65,66,67,68],"Shock","Shock, Septic","Hypotension","Hypotension Symptomatic","Hypovolemia","Hypovolemic Shock","Hypovolemic",[70,71,72,73,74],"Peripherally infused noradrenaline","Fluid therapy","Fluid treatment","Non-hemorrhagic shock and hypotension","Emergency Department","2025-06-26",{"date":77,"type":38},"2025-07-01",{"date":79,"type":38},"2023-12-08",{"date":81,"type":21},"2027-01-31",{"name":83,"class":45},"Odense University Hospital",8,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":97,"conditions":98,"keywords":102,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":46},"100594699","pleth-variability-index-for-predicting-low-blood-pressure-during-maintenance-hemodialysis-100594699","NCT07022847","Pleth Variability Index for Predicting Low Blood Pressure During Maintenance Hemodialysis","The Value of Pleth Variability Index in Predicting Hypotension During Maintenance Hemodialysis: A Prospective Observational Multicenter Study","PVI-HD","Inclusion Criteria:\n\n* Adults aged 18 to 80 years.\n* Diagnosis of end-stage renal disease and undergoing maintenance hemodialysis for more than 3 months.\n* Able and willing to provide informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Severe cardiac arrhythmias or significant peripheral vascular disease that may interfere with PVI measurements.\n* Local edema, skin lesions, or other conditions that prevent accurate PVI monitoring.\n* History of hemodynamic instability unrelated to dialysis.\n* Pregnant or breastfeeding women.\n* Known allergy or contraindication to materials used in the hemodialysis circuit.\n* Unable to cooperate with study procedures.\n* Participation in another interventional clinical study within the past 30 days.","80 Years",{"count":95,"type":21},200,"OBSERVATIONAL","What is this study about? We are studying whether the Pleth Variability Index (PVI)-a simple, non-invasive measurement from a pulse oximeter-can help predict low blood pressure (hypotension) during routine maintenance hemodialysis. Low blood pressure during dialysis is a common and potentially serious complication. Our goal is to find out if monitoring PVI can help identify patients at risk, so that early action can be taken.\n\nWho can join? Adults aged 18 to 80 years. Patients who have been receiving maintenance hemodialysis regularly for more than 3 months.\n\nThose who are willing and able to participate and sign an informed consent form.\n\nWho cannot join? Patients with severe heart rhythm problems, severe peripheral circulation problems, or swelling that makes PVI measurement unreliable.\n\nPatients who are pregnant or breastfeeding. Patients allergic to the dialysis filter or unable to cooperate with the study procedures.\n\nWhat will happen during the study? PVI Measurement: Your PVI will be checked with a simple fingertip device before starting dialysis and again 30 minutes after dialysis begins.\n\nBlood Pressure Monitoring: Your blood pressure will be closely watched throughout the dialysis session.\n\nData Collection: Information about your age, medical history, medications, lab results, dialysis settings, and other standard measurements will be recorded.\n\nWhat are the benefits and risks? Benefits: By identifying patients at higher risk for low blood pressure during dialysis, the study may lead to safer and more comfortable dialysis treatment in the future.\n\nRisks: All measurements used in this study are safe and non-invasive, with no extra risk compared to routine care.\n\nYour Rights and Safety Participation is completely voluntary-you may leave the study at any time without affecting your medical care.\n\nThe study has been reviewed and approved by the hospital's ethics committee. Your privacy and personal data will be strictly protected.",[27,99,100,101],"Hemodialysis","End-Stage Renal Disease Requiring Haemodialysis","Intradialytic Hypotension",[103,99,101,104,105,106,107,108],"Pleth Variability Index","Blood Pressure Monitoring","End-Stage Renal Disease","Non-invasive Monitoring","Predictive Marker","Maintenance Dialysis","2025-06-07",{"date":111,"type":38},"2025-06-15",{"date":113,"type":38},"2025-02-01",{"date":115,"type":21},"2025-06-30",{"name":117,"class":45},"First Affiliated Hospital of Wannan Medical College",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":127,"conditions":128,"keywords":132,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":144},"100420916","prehospital-management-of-hypotensive-trauma-in-hems-100420916","NCT04760977","Prehospital Management of Hypotensive Trauma in HEMS","SPITFIRE","Inclusion Criteria:\n\n* Age \\> 18 years\n* Witnessed traumatic event managed by HEMS\n* Shock at first evaluation (Systolic blood pressure \\\u003C 90 mmHg)\n* Suspect or obvious ongoing haemorrage\n\nExclusion Criteria:\n\n* Patients in cardiac arrest at HEMS arrival in which resuscitation is not started or interrupted by HEMS crew",{"count":126,"type":21},500,"Up to today, inadequate evidences and knowledge exist about the best prehospital management of hypotensive trauma patients and its clinical consequence on the in-hospital recovery and mortality.\n\nAlso new emerging therapies such as prehospital blood transfusion and REBOA (resuscitative endovascular balloon occlusion of the aorta) are lacking strong evidences in, eventually, reducing hospital mortality and improving outcomes.\n\nMoreover, prehospital emergency medicine is throughout Italy an heterogeneous system that has no unique standard operating procedures and, even among HEMS (helicopter emergency medical service), management and therapies on complex trauma patients may vary upon local policies.\n\nWith this study we aim to enroll hypotensive trauma patients and study factors of prehospital rescue that can be associated with in-hospital mortality and recovery, eventually even with hospital outcome. For each patients data as demographic, kind of trauma (mechanism, injury scores), therapies and maneuvers will be recorded and then analyzed in comparison with in-hospital data such as need for transfusion, ABG parameters, length of stay (in-ward and ICU), need of therapies like invasive ventilation and renal replacement therapy, recovery and outcome",[27,129,130,131],"Wounds and Injuries","Emergencies","Critical Care",[133,129,130,131],"Transportation of Patients","2024-08-10",{"date":136,"type":38},"2024-08-13",{"date":138,"type":38},"2021-05-01",{"date":140,"type":21},"2026-05-01",{"name":142,"class":143},"Azienda Usl di Bologna","OTHER_GOV",16]